Last reviewed · How we verify
EN41-UGR7C HIV vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
EN41-UGR7C HIV vaccine (EN41-UGR7C HIV vaccine) — PX'Therapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| EN41-UGR7C HIV vaccine TARGET | EN41-UGR7C HIV vaccine | PX'Therapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- EN41-UGR7C HIV vaccine CI watch — RSS
- EN41-UGR7C HIV vaccine CI watch — Atom
- EN41-UGR7C HIV vaccine CI watch — JSON
- EN41-UGR7C HIV vaccine alone — RSS
Cite this brief
Drug Landscape (2026). EN41-UGR7C HIV vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/en41-ugr7c-hiv-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab